Apichai Khongphatthanayothin

Apichai Khongphatthanayothin

Auto-generated profile, based on publicly available information

Apichai Khongphatthanayothin

Department of Medicine, Center of Excellence in Arrhythmia Research, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2023 in Circulation
Verified
Journal Article
Open access
KNKoonlawee Nademanee
Koonlawee Nademanee
FCFa-Po Chung
Fa-Po Chung
FSFrederic Sacher
Frederic Sacher
ANAkihiko Nogami
Akihiko Nogami
HNHiroshi Nakagawa
Hiroshi Nakagawa
MHMichel Haïssaguerre
Michel Haïssaguerre
Background: Treatment options for high-risk Brugada syndrome (BrS) with recurrent ventricular fibrillation (VF) are limited. Catheter ablation is increasingly performed but a large study with long-term outcome data is lacking. We report the results of the multicenter, international BRAVO (Brugada Ablation of VF Substrate Ongoing Registry) for treatment of high-risk symptomatic BrS. Methods: We enrolled 159 patients (median age 42 years; 156 male) with BrS and spontaneous VF in BRAVO; 43 (27%) of them had BrS and early repolarization pattern. All but 5 had an implantable cardioverter-defibrillator for cardiac arrest (n=125) or syncope (n=34). A total of 140 (88%) had experienced numerous implantable cardioverter-defibrillator shocks for spontaneous VF before ablation. All patients underwent a percutaneous epicardial substrate ablation with electroanatomical mapping except for 8 who underwent open-thoracotomy ablation. Results: In all patients, VF/BrS substrates were recorded in the epicardial surface of the right ventricular outflow tract; 45 (29%) patients also had an arrhythmic substrate in the inferior right ventricular epicardium and 3 in the posterior left ventricular epicardium. After a single ablation procedure, 128 of 159 (81%) patients remained free of VF recurrence; this number increased to 153 (96%) after a repeated procedure (mean 1.2±0.5 procedures; median=1), with a mean follow-up period of 48±29 months from the last ablation. VF burden and frequency of shocks decreased significantly from 1.1±2.1 per month before ablation to 0.003±0.14 per month after the last ablation ( P <0.0001). The Kaplan-Meier VF-free survival beyond 5 years after the last ablation was 95%. The only variable associated with a VF-free outcome in multivariable analysis was normalization of the type 1 Brugada ECG, both with and without sodium-channel blockade, after the ablation (hazard ratio, 0.078 [95% CI, 0.008 to 0.753]; P =0.0274). There were no arrhythmic or cardiac deaths. Complications included hemopericardium in 4 (2.5%) patients. Conclusions: Ablation treatment is safe and highly effective in preventing VF recurrence in high-risk BrS. Prospective studies are needed to determine whether it can be an alternative treatment to implantable cardioverter-defibrillator implantation for selected patients with BrS. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04420078.

1 November 2007 in Pediatric Critical Care Medicine
Verified
Journal Article
Closed access
AKApichai Khongphatthanayothin
Apichai Khongphatthanayothin
PLPornthep Lertsapcharoen
Pornthep Lertsapcharoen
PSPentip Supachokchaiwattana
Pentip Supachokchaiwattana
VLVidhawas La-Orkhun
Vidhawas La-Orkhun
AKAree Khumtonvong
Aree Khumtonvong
CPChitsanu Pancharoen
Chitsanu Pancharoen
Objectives: To determine the prevalence of myocardial depression and its effect on the clinical severity in patients with dengue hemorrhagic fever. Design: Clinical study. Setting: King Chulalongkorn Memorial Hospital, Bangkok, Thailand. Patients: Ninety-one children (age 10.5 ± 2.9 yrs, male/female = 52/39) with serologically or polymerase chain reaction-proven dengue virus infection. Interventions: Left ventricular ejection fraction (EF) was measured. The proportions of patients with EF <50% were identified in patients with dengue fever (DF, n = 30), dengue hemorrhagic fever without shock (DHF, n = 36), and dengue shock syndrome (DSS, n = 25). Comparisons of clinical findings were made among DSS patients with depressed ventricular function (EF <50%), fair ventricular function (EF ≥50% and <60%), and good ventricular function (EF ≥60%). Serum troponin T was analyzed in nine patients. Measurements and Main Results: EF during toxic stage was significantly lower in patients with DSS than DHF, and lower in DHF than DF (p = .05) with rapid recovery within 24–48 hrs. EF <50% was found in 6.7%, 13.8%, and 36% of patients with DF, DHF, and DSS during the toxic stage, respectively (p = .01). DSS patients with poor ventricular function had significantly more tachycardia and hepatomegaly. While end-diastolic volumes were similarly reduced, patients with lower EF tended to have lower cardiac output, required more aggressive intravenous fluid resuscitation, developed larger pleural effusion, and had higher incidence of respiratory embarrassment. No patient had elevated troponin T level. Conclusions: Transient myocardial depression is not uncommon in patients with DSS. Cardiac dysfunction in children with DSS may contribute to the clinical severity and the degree of fluid overload in these patients.

21 February 2003 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
AKApichai Khongphatthanayothin
Apichai Khongphatthanayothin
MSMonnipa Suesaowalak
Monnipa Suesaowalak
SMSunthorn Muangmingsook
Sunthorn Muangmingsook
PBParvapan Bhattarakosol
Parvapan Bhattarakosol
CPChitsanu Pancharoen
Chitsanu Pancharoen

1 December 2020 in Heart Rhythm
Verified
Journal Article
Closed access
PMPattarapong Makarawate
Pattarapong Makarawate
CGCharlotte Glinge
Charlotte Glinge
AKApichai Khongphatthanayothin
Apichai Khongphatthanayothin
RWRoddy Walsh
Roddy Walsh
JMJohn Mauleekoonphairoj
John Mauleekoonphairoj
KNKoonlawee Nademanee
Koonlawee Nademanee

1 December 2020 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
PDF file
CCChanatjit Cheawsamoot
Chanatjit Cheawsamoot
CPChureerat Phokaew
Chureerat Phokaew
WCWanna Chetruengchai
Wanna Chetruengchai
PCPoonchavist Chantranuwat
Poonchavist Chantranuwat
SPSarinya Puwanant
Sarinya Puwanant
Vorasuk ShotelersukVorasuk Shotelersuk
Vorasuk Shotelersuk

28 June 2006 in Japanese Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
AKApichai Khongphatthanayothin
Apichai Khongphatthanayothin
PPPiyawan Phumaphuti
Piyawan Phumaphuti
KTKriangsak Thongchaiprasit
Kriangsak Thongchaiprasit
YPYong Poovorawan
Yong Poovorawan
The purpose of this study was to measure the serum level of sICAM-1 and sE-selectin as markers for endothelial damage in patients with dengue fever (DF) and dengue hemorrhagic fever (DHF). Twenty-nine patients with serologically-proven dengue virus infection (age 10.6 ± 2.4 years, 55% male, DF = 13 and DHF = 16) were enrolled. Serum samples were collected from 25 healthy children (age 10.6 ± 2.3 years, 40% male) as the control group. A follow-up was done at a mean interval of 15.9 ± 1.6 days. The level of sICAM-1 at the toxic stage was significantly elevated compared to its level at the follow-up (494.1 ± 107.4 versus 358.2 ± 67.6 ng/ml, P = 0.001), but no difference was found between patients with DF and patients with DHF (444.1 ± 158.0 versus 465.1 ± 154.6 ng/ml, P = 0.74). The sICAM-1 level at the follow-up was similar to that of the control group (396.9 ± 113.0 ng/ml, P = 0.56). The level of sE-selectin at the toxic stage was not different from its level at the follow-up (75.9 ± 33.0 versus 75.5 ± 31.7 ng/ml, P = 0.96), and no difference was found between the DF group and the DHF group (64.1 ± 25.7 versus 78.8 ± 39.9 ng/ml, P = 0.30). These levels were not elevated compared to the sE-selectin level that was determined in 8 patients in the control group (94.7 ± 20.5 ng/ml, P = 0.12). In conclusion, there is evidence of endothelial activation by an increased sICAM-1 level in patients with dengue virus infection. However, the degree of endothelial activation alone may be similar for patients with DF and patients with DHF, and this fact by itself cannot explain the difference between the two clinical syndromes of dengue virus infection. The sE-selectin level was not elevated for patients included in this study.